Document is current

Article History

Received: 20 September 2024

Accepted: 26 December 2024

First Online: 23 January 2025

Declarations

:

: Chih-Hung Hsu reports consulting or advisory role from Bristol-Myers Squibb, Ono Pharmaceutical, Merck Serono, Roche/Genentech, AstraZeneca and Daiichi Sankyo; travel, accommodation, expense from Daiichi Sankyo; honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Merck Sharp & Dohme, Roche, and Eisai; research funding (institution) from Ono Pharmaceutical, AstraZeneca, Merck Sharp & Dohme, Merck Serono, Taiho Pharmaceutical, Bristol-Myers Squibb, BeiGene, Nucana, Jonson & Johnson, Roche/Genentech, NGM Pharmaceuticals, Eucure Biopharma, and Surface Oncology. Ken Kato reports funding to the institution from Merck Sharp & Dohme Corp (MSD), Ono Pharmaceuticals, Bristol Myers Squibb (BMS), Beigene, Shionogi, Merck Biopharma, Oncolys BioPharma, Daiichi Sankyo, Novartis, Taiho Pharmaceutical, Janssen, AstraZeneca, and Chugai.

: This work is a review article summarizing published clinical trial results and discussing their potential impact on future esophageal squamous cell carcinoma treatments.